Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.63 |
| ▸ | LMNA | P02545 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 3/20 | 0.58 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10144696 | 0.84 | GAA (0.61) | ALDH1A1LMNASMN1; SMN2GAAABCB1 | |
| SCHEMBL13419901 | 0.79 | ALDH1A1 (0.63) | ALDH1A1SMN1; SMN2GAAMAPTHTT | |
| SCHEMBL10113701 | 0.75 | ADORA2B (0.64) | ALDH1A1GAAHTT | |
| SCHEMBL7691437 | 0.74 | ALDH1A1 (0.65) | ALDH1A1SMN1; SMN2GAAMAPTKDM4E | |
| SCHEMBL7695378 | 0.71 | ALDH1A1 (0.67) | ALDH1A1LMNASMN1; SMN2GAAABCB1 | |
| SCHEMBL16497681 | 0.71 | ALDH1A1 (0.57) | ALDH1A1LMNASMN1; SMN2ABCB1HSD17B10 | |
| SCHEMBL10113002 | 0.70 | DHFR (0.72) | ALDH1A1LMNASMN1; SMN2ALOX12HTT | |
| SCHEMBL7695596 | 0.69 | TP53 (0.61) | ALDH1A1LMNASMN1; SMN2GAAABCB1 | |
| SCHEMBL7694783 | 0.69 | ALDH1A1 (0.72) | ALDH1A1SMN1; SMN2GAAMAPTHSD17B10 | |
| SCHEMBL3168404 | 0.69 | CA1 (0.79) | ALDH1A1LMNAGAAHSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | BIOMARIN PHARMACEUTICAL INC. | 2012-04-26 | — | — | US | disclosed |
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | BIOMARIN PHARMACEUTICAL INC. | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | ENGASE, GALNT1, GALNT13 | ALDH1A1 2125/4885LMNA 4109/4885SMN1; SMN2 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.